Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
Gain Therapeutics, Inc. (Nasdaq: GANX) is preparing to showcase its pioneering advancements in allosteric therapies at the BTIG Annual Virtual Biotechnology Conference. This event, which will be held over two days, promises to bring together industry leaders to discuss the future of biotechnology and innovations in therapeutic development.
Event Insights
The management team of Gain Therapeutics will engage in a fireside chat and participate in one-on-one meetings during this highlighted event. Those attending can anticipate an insightful discussion regarding Gain's latest projects and the broader implications of their research in the biotechnology sector. Attendees are encouraged to connect with the management team via their BTIG banking representative for personalized discussions.
Presentation Details
Set for Wednesday, the 30th, in the vibrant atmosphere of digital biotechnology exchange, the presentation is scheduled for 3:20 PM ET. The event provides an excellent opportunity for investors and professionals to gain deeper insights into the innovative directions that Gain Therapeutics is pursuing.
About Gain Therapeutics
Gain Therapeutics is a forward-thinking, clinical-stage biotechnology company focused on developing a new generation of allosteric small molecule therapies. Their lead candidate, GT-02287, is undergoing assessment for its effectiveness in addressing Parkinson's disease, potentially benefiting patients with or without a GBA1 mutation. Besides Parkinson’s, it exhibits promise for other challenging conditions including Gaucher’s disease, Alzheimer’s, and dementia with Lewy bodies.
Innovative Therapy Development
One of Gain’s remarkable attributes is its advanced Magellan™ platform, which facilitates the discovery of novel therapies aimed at restoring protein function. This pioneering approach positions Gain Therapeutics at the frontier of treatment solutions for complex diseases ranging from neurodegenerative disorders to various forms of cancer.
Investor Relations Information
For any inquiries relating to investor communications, the company can be reached through Apaar Jammu, Manager of Investor Relations and Public Relations. Any interested parties may contact him directly via email.
Contact Details
Email: ajammu@gaintherapeutics.com
Further details regarding the event can be explored through the company’s communication team, which aims to ensure transparent relations with investors. Their commitment reflects an understanding of the importance of timely and accurate information dissemination.
Media Relations
For media inquiries, Gain Therapeutics has partnered with Russo Partners LLC, represented by Nic Johnson and Elio Ambrosio, who are available for direct communication. The media team is dedicated to providing insights and updates regarding the company’s mission and vision in developing life-changing therapies.
Connect with the Media
Media Contact: nic.johnson@russopartnersllc.com
Frequently Asked Questions
What is the main focus of Gain Therapeutics?
Gain Therapeutics concentrates on creating advanced allosteric therapies for conditions like Parkinson’s and other neurodegenerative diseases.
When will the presentation at BTIG Conference occur?
The presentation is scheduled for Wednesday, July 30, at 3:20 PM ET.
Who can attend the one-on-one meetings with Gain management?
Registered attendees of the BTIG Conference can request these personalized meetings through their BTIG banking representatives.
How does Gain Therapeutics utilize its Magellan™ platform?
Gain Therapeutics uses the Magellan™ platform to discover and develop specific small molecule modulators that can alter protein functionality for therapeutic effects.
How can investors get more information about Gain Therapeutics?
Investors can contact Apaar Jammu or the media relations team for detailed inquiries about the company's developments and investor engagement.
